Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guo-Ming Shi

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Hepatology (Baltimore, Md.)|September 5, 2015
Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transitionLiu-Xiao Yang, Qiang Gao, Jie-Yi Shi, et al.
Theranostics|August 2, 2019
Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk FactorsJia-Cheng Lu, Hai-Ying Zeng, Qi-Man Sun, et al.
Hepatology International|November 23, 2022
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasionXian-Long Meng, Jia-Cheng Lu, Hai-Ying Zeng, et al.
Experimental Hematology & Oncology|June 17, 2026
Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinomaShan-Ru Feng, En-Fu Dong, Zheng Gao, et al.
Signal Transduction and Targeted Therapy|March 17, 2023
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 studyGuo-Ming Shi, Xiao-Yong Huang, Dong Wu, et al.
Frontiers in Immunology|September 16, 2021
CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic CholangiocarcinomaXiao-Jun Guo, Jia-Cheng Lu, Hai-Ying Zeng, et al.
Clinical and Translational Medicine|May 13, 2025
Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancerChen Liang, Mu Ye, Lei Yu, et al.
Hepatology (Baltimore, Md.)|January 6, 2015
Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progressionJia-Bin Cai, Guo-Ming Shi, Zhao-Ru Dong, et al.
Gastroenterology|February 8, 2014
Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patientsQiang Gao, Ying-Jun Zhao, Xiao-Ying Wang, et al.
Journal of Translational Medicine|October 1, 2024
Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumorsDao-Han Zhang, Chen Liang, Shu-Yang Hu, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Hepatology (Baltimore, Md.)|September 5, 2015
Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transitionLiu-Xiao Yang, Qiang Gao, Jie-Yi Shi, et al.
Theranostics|August 2, 2019
Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk FactorsJia-Cheng Lu, Hai-Ying Zeng, Qi-Man Sun, et al.
Hepatology International|November 23, 2022
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasionXian-Long Meng, Jia-Cheng Lu, Hai-Ying Zeng, et al.
Experimental Hematology & Oncology|June 17, 2026
Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinomaShan-Ru Feng, En-Fu Dong, Zheng Gao, et al.
Signal Transduction and Targeted Therapy|March 17, 2023
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 studyGuo-Ming Shi, Xiao-Yong Huang, Dong Wu, et al.
Frontiers in Immunology|September 16, 2021
CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic CholangiocarcinomaXiao-Jun Guo, Jia-Cheng Lu, Hai-Ying Zeng, et al.
Clinical and Translational Medicine|May 13, 2025
Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancerChen Liang, Mu Ye, Lei Yu, et al.
Hepatology (Baltimore, Md.)|January 6, 2015
Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progressionJia-Bin Cai, Guo-Ming Shi, Zhao-Ru Dong, et al.
Gastroenterology|February 8, 2014
Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patientsQiang Gao, Ying-Jun Zhao, Xiao-Ying Wang, et al.
Journal of Translational Medicine|October 1, 2024
Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumorsDao-Han Zhang, Chen Liang, Shu-Yang Hu, et al.
Pageof 10